The therapeutic efficacy of human insulin (recombinant DNA) was compared with that of purified porcine insulin (PPI) in seven male subjects with previously treated insulin-dependent diabetes mellitus. In a random crossover design the patients received either PPI or human insulin during one of two consecutive 7-day periods of intensive insulin therapy. Control was evaluated on days 6 and 13. Tissue sensitivity and responsiveness to the study insulins were determined by insulin dose-response studies performed using the euglycemic glucose clamp on days 7 and 14. Insulin dose and all measures of control on days 6 and 13 were not statistically different between treatments. When the insulin dose-response studies during each treatment were compared there were no differences between them. Thus, in previously treated patients with insulin-dependent diabetes, undergoing brief but intensive insulin therapy with continuous subcutaneous insulin infusion, human insulin is as clinically efficacious as PPI. Furthermore, insulin sensitivity and responsiveness, as assessed by dose-response studies during the euglycemic glucose clamp were equivalent for both insulins.
The Therapeutic Efficacy of Human Insulin (recombinant DNA) in Patients with Insulin-dependent Diabetes Mellitus: A Comparative Study with Purified Porcine Insulin
Daniel C Howey, S Edwin Fineberg, Phyllis A Nolen, Margaret I Stone, Reid G Gibson, Naomi S Fineberg, John A Galloway; The Therapeutic Efficacy of Human Insulin (recombinant DNA) in Patients with Insulin-dependent Diabetes Mellitus: A Comparative Study with Purified Porcine Insulin. Diabetes Care 1 November 1982; 5 (Supplement_2): 73–77. https://doi.org/10.2337/diacare.5.2.S73
Download citation file: